Expression and activation of the farnesoid X receptor in the vasculature
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The farnesoid X receptor/bile acid receptor (FXR) is a recently discovered member of the nuclear hormone superfamily. FXR ligands have been proposed as targets in cardiovascular disease, regulating cholesterol metabolism and bile acid transport and metabolism in the liver and gastrointestinal tract. When we used a human cardiovascular tissue array, we found that FXR is expressed in a variety of normal and pathological human tissue. Particularly high levels of FXR were found in the vasculature and in a number of different metastatic cancers, as well as the previously identified target tissues of the liver, small intestine, and kidney. In vitro , FXR is present in rat and human vascular smooth muscle cells. When treated with a range of FXR ligands, vascular smooth muscle cells undergo apoptosis in a manner that correlates with the ligands' ability to activate FXR. Furthermore, FXR activators induce mRNA for the FXR target genes, phospholipid transfer protein, and the small heterodimer partner. FXR therefore is a functional protein in the vasculature that may provide a direct target for the treatment of proliferative and dyslipidaemic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
Identification of Farnesoid X Receptor β as a Novel Mammalian Nuclear Receptor Sensing Lanosterol
Otte, K., Kranz, H., Kober, I., Thompson, P., Hoefer, M., Haubold, B., Remmel, B., Voss, H., Kaiser, C., Albers, M., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.3.864-872.2003 · Cited by 176
Cited by
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
“Recent evidence suggests that FXR activation may play a role in decreasing inflammation of the vasculature, which is critically involved in the progression of atherosclerosis (Bishop-Bailey et al., 2004; Li et al., 2007).”
BackgroundBile acid receptors as targets for drug development
Schaap, F. G., Trauner, M., & Jansen, P. L. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.151 · Cited by 696
Mouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688
Role of gut microbiota in atherosclerosis
Jonsson, A. L., & Bäckhed, F. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.183 · Cited by 644
LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
Kalaany, N. Y., & Mangelsdorf, D. J. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.033104.152158 · Cited by 615
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 544
HDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Zeng, H., Umar, S., Rust, B., Lazarova, D., & Bordonaro, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051214 · Cited by 480
“Similarly, compared with WT mice, dextran-sulfate-sodium induced colitis was more severe in PXR−/− mice [103] although the action of these receptors (TGR5, FXR, PXR) may also be determined by cell types, tissue site, age, and immunological context [104,105].”
BackgroundMolecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Beyond intestinal soap—bile acids in metabolic control
Kuipers, F., Bloks, V. W., & Groen, A. K. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.60 · Cited by 454
FXR: a metabolic regulator and cell protector
Wang, Y.-D., Chen, W.-D., Moore, D. D., & Huang, W. (2008) · Cell Research · doi:10.1038/cr.2008.289 · Cited by 389
Immune regulation by microbiome metabolites
Kim, C. H. (2018) · Immunology · doi:10.1111/imm.12930 · Cited by 375
Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer
Li, T., & Apte, U. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2015.04.003 · Cited by 333
Geier, A., Wagner, M., Dietrich, C. G., & Trauner, M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.014 · Cited by 314
Deciphering the nuclear bile acid receptor FXR paradigm
Modica, S., Gadaleta, R. M., & Moschetta, A. (2010) · Nuclear Receptor Signaling · doi:10.1621/nrs.08005 · Cited by 295
Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
Porez, G., Prawitt, J., Gross, B., & Staels, B. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024794 · Cited by 286
Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease
Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269
Bile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 258
FXR signaling in metabolic disease
Zhang, Y., & Edwards, P. A. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.11.015 · Cited by 209
Pu, J., Yuan, A., Shan, P., Gao, E., Wang, X., Wang, Y., Lau, W. B., Koch, W., Ma, X.-L., & He, B. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs011 · Cited by 200
“More importantly, recent evidence suggests the presence of FXR in the vasculature,(9) with important roles in vascular physiology/pathology.(9,10) However, the potential function of FXR in the heart remains largely unknown.”
BackgroundFarnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration
Li, Y. T. Y., Swales, K. E., Thomas, G. J., Warner, T. D., & Bishop-Bailey, D. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.152694 · Cited by 171
Self-citationHow bile acids and the microbiota interact to shape host immunity
Lee, M. H., Nuccio, S.-P., Mohanty, I., Hagey, L. R., Dorrestein, P. C., Chu, H., & Raffatellu, M. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01057-x · Cited by 143
Ratziu, V., Harrison, S. A., Loustaud-Ratti, V., Bureau, C., Lawitz, E., Abdelmalek, M., Alkhouri, N., Francque, S., Girma, H., Darteil, R., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.023 · Cited by 101
Goto, T., Itoh, M., Suganami, T., Kanai, S., Shirakawa, I., Sakai, T., Asakawa, M., Yoneyama, T., Kai, T., & Ogawa, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-26383-8 · Cited by 88
Bacterial metabolites directly modulate farnesoid X receptor activity
Zhang, X., Osaka, T., & Tsuneda, S. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0045-y · Cited by 34
“It is abundantly expressed in the liver, intestine, kidney, and adrenals [2, 3], but is also expressed in fat, the stomach, lungs and heart [3, 4].”
BackgroundFarnesoid X receptor alpha: a molecular link between bile acids and steroid signaling
Baptissart, M., Vega, A., Martinot, E., Baron, S., Lobaccaro, J.-M. A., & Volle, D. H. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1387-0 · Cited by 32
On the Pharmacology of Farnesoid X Receptor Agonists: Give me an "A", Like in "Acid"
Hambruch, E., Kinzel, O., & Kremoser, C. (2016) · Nuclear Receptor Research · doi:10.11131/2016/101207 · Cited by 3
Metadata
- Authors
- Bishop-Bailey, D., Walsh, D. T., & Warner, T. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-02-27
- Volume
- 101
- Issue
- 10
- Pages
- 3668-3673
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2024685706
- Cited by
- 242
- References
- 5
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.